Dog owner convinced one sweet ingredient cured her pet's cancer
A dog diagnosed with an aggressive cancer has made a recovery after her owner started spreading honey on her food. Libby Basford's golden cocker spaniel, Matilda, was diagnosed with oral melanoma and the vet booked Matilda in for surgery.
The painful lump in the back corner of her mouth was removed successfully. But in less than five months, the cancerous growth had returned and doubled in size, leading to her undergoing a second surgery.
After being removed again, small tumours appeared all over Matilda's mouth. Vets advised Libby that a third surgery would mean that a large portion of Matilda's mouth would be removed. Libby spoke to a holistic vet, who suggested she try a natural honey, which can be squeezed onto food.
READ MORE: Drivers using blue badges warned 'we cannot continue to ignore this issue'
READ MORE: Tesco and Asda will offer full refunds without receipts if bring popular snack back after recall
After six weeks, the tumours inside Matilda's mouth shrank and eventually disappeared. Libby said: "There is no doubt in my mind that honey is powerful stuff. Personally, I am convinced it was the honey that saved Matilda and made the melanomas in her mouth shrink and disappear completely.
'I didn't want Matilda to have chemo and declined an oral melanoma vaccine. Matilda is now walking, jumping and racing - a real testament to the power of the honey.We have had two previous dogs who succumbed to cancer, and I really wish we had known about it then.'
Matilda was nine at the time she was diagnosed in 2021. Four years later, aged 13, she is a healthy dog with no signs of cancer. Libby gives her a single maintenance dose of honey every week.
The honey is a natural product which is high in a potent iminosugar called Iminose A. Dr Robert Nash, owner of Dr Nash Glyco Health, said: 'Iminosugars have not been studied by many scientists as they are difficult to detect and synthesise, yet they can have potent and varied effects.
'They are in many foods and herbal medicines, but are rarely noticed and measured. Many modern food plant varieties and supplements have had the iminosugars removed."
Experts say honey has been linked to better health, although there is no evidence it can 'cure cancer'.
Honey contains compounds like flavonoids and phenolic acids, which can reduce inflammation and oxidative stress — both of which are linked to cancer development. Honey is known for promoting wound healing and preventing infections, which can be helpful in cancer patients with wounds or compromised immunity.
Some studies in test tubes and animals suggest that honey might inhibit the growth of certain cancer cells (like breast, colon, or prostate cancer cells), likely due to its antioxidant and pro-apoptotic (cell-killing) effects. But these are not clinical studies in humans.
Iminosugars mimic the shape and size of sugars, so they can bind to enzymes that normally process sugars, particularly glycosidases (enzymes that break down complex carbohydrates). They act as competitive inhibitors, blocking the enzyme's activity.
Some iminosugars are used to treat illnesses and viruses, and have been found to reduce blood sugar spikes.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
43 minutes ago
- Medscape
Experts Suggest NHS Heart Risk Checks from Age 25
MANCHESTER — Cardiovascular health assessments should begin much earlier, focusing on lifetime risk rather than just their 10-year projections, experts said at the British Cardiovascular Society Annual Conference 2025. 'We are looking at cardiovascular risk assessment far too late', said Beverley Bostock, a Queen's nurse and president-elect of the Primary Care Cardiovascular Society (PCCS). Bostock was introducing a conference session titled '25 is the new 40: shifting the focus to lifetime risk'. Prevention Focus in NHS Strategy Derek Connolly, a consultant cardiologist in private practice in Birmingham, said he hoped this approach would be supported in England's 10 Year Health Plan for the NHS. 'There is going to be an enormous emphasis, we think, going forward, on preventive cardiology – and it's about time that that was the case', he said. Connolly said that the team behind the plan were 'very into prevention' and 'had done the math' on the potential benefits of well-known strategies such as lifestyle interventions. By addressing modifiable risk factors earlier and throughout the life course, 'they've worked out that if we do a lot of these things, not only do we save lives, but we save money, and we keep people in work and paying taxes', he said. Rising CVD Burden Recent data in the European Journal of Preventative Cardiology , highlighted during the session, projected a 90% increase in global cardiovascular disease (CVD) prevalence over the next 25 years. CVD-related deaths are expected to rise from 20.5 million in 2025 to 35.6 million in 2050 – a 73.4% increase in crude mortality. Current NHS Risk Assessments The NHS currently assesses 10-year CVD risk from age 40, repeating every 5 years until age 74. This is typically measured using the cardiovascular risk score (QRISK 2), embedded in GP consulting software, although QRISK 3 and QRISK lifetime offer greater predictive power. Jim Moore "CVD risk is predicated around a lifetime exposure to risk factors,' said Jim Moore, a recently retired GP with a special interest in cardiovascular medicine. 'Just modest changes in those risk factors — your lipid profile or blood pressure — can, we know independently, and in combination, improve your outcomes.' Moore, a past president of the PCCS, said 10-year calculators may underestimate risk in those under 40, even when significant risk factors are present. Lifetime calculators could be 'persuasive' tools in patient consultations, he argued, with results helping to steer discussions towards lifestyle changes and risk factor modifications. The key message, he said, was the need for a holistic approach, which was 'something that we really do not see routinely happening in my area within primary care'. Case for Earlier Screening Scott Murray, a consultant cardiologist at University Hospitals of Liverpool Group and former president of the British Association for Cardiovascular Prevention and Rehabilitation, made the case for assessing CV risk in people under 40. Scott Murray Modern lifestyles characterised by sedentary behaviour, poor dietary habits, and increasing stress were contributing to rising CVD in younger populations. 'We're seeing more obesity, insulin resistance, dyslipidaemia, and hypertension', Murray said. 'I like to think of it a bit like this: so, you've got your genetic predisposition – genetics loads the gun, and your environment pulls the trigger.' Murray proposed age 25 as a theoretical "sweet spot" for screening. 'There's a sort of lifestyle transition at age 25 into more independent adulthood, more able to potentially think about family responsibilities.' At age 25, most people have finished puberty and reached physiological maturity. Data suggests that starting CVD screening at this age would be cost-effective by maximising opportunities for lower-cost interventions, according to Murray. However, he acknowledged potential difficulties in engaging 25-year-olds when NHS health checks for over-40s have not reached hoped-for targets. Targeted Approach Laura Ormesher, a National Institute for Health and Care Research academic clinical lecturer at the University of Manchester, suggested that pregnancy could be an ideal time to educate younger women about lifestyle-related CVD risk. 'We know that adverse pregnancy outcomes increase the risk of cardiovascular disease, and I think we've got to make the most of that opportunity during the pregnancy,' she said. She added that the postnatal period — typically 'a little bit less complicated for women' — is a time when many felt 'empowered to try and improve their long-term health for their child and their family,' Ormesher added. Dr Sundhya Raman Dr Sundhya Raman, a lifestyle physician, acknowledged that universal health checks from age 25 might be too ambitious but supported a targeted strategy. 'Maybe we need to target the higher risk individuals with strong family histories of raised BMI,' she said. 'There is great potential for when you educate one person, you educate a family, you educate a community,' Raman added. Moore has received honoraria for participation in educational activities and advisory boards from AstraZeneca, Amarin, Boehringer Ingelheim, Eli Lilly and Company, Daiichi-Sankyo, Novartis and Medtronic. Raman acknowledged she was a founder of My Wellness Doctor and My Weight Loss Doctor Clinic . Murray declared being the founder and medical director for Venturi Cardiology but had no relevant conflicts of interest. Ormesher had no conflicts to declare.


Time Business News
an hour ago
- Time Business News
Fast Relief from Sleepless Nights – Sleeping Pills with Next Day UK Delivery
Your entire life will suffer negative effects when you lack sleep because it destroys your mood and energy as well as your concentration and your ability to function during daylight hours. Among the many people experiencing sleep difficulties, you probably search for an effective and quick solution for better rest. The wide range of sleeping pills in the UK is now more available through trusted online pharmacies that provide next-day UK delivery. The waiting time for relief is now reduced because you receive it without delay. People throughout the UK benefit from buying sleeping pills online for next-day delivery which revolutionizes their management approach to insomnia and sleep-related disturbances. The purpose ofSleeping Pills UK is to assist patients in quickest sleep onset and optimal sleep duration resulting in improved quality rest. Multiple types of sleeping pills exist in the market and patients can obtain their medicines through both prescribed drug channels and no prescribed channels. Acute insomnia together with short-term sleep problems requires medical prescription of both Zopiclone and Zolpidem medications. These medications now constitute some of the most effective sleeping pills present in the UK market. The market provides over-the-counter products for individuals facing periodic sleep issues. The market offers two main types of medications including antihistamine and herb-based formulas suitable for those who prefer gentler treatments. When you do not sleep well, time becomes important. Waiting for several days to get help can worsen symptoms such as anxiety, poor concentration and low productivity. This is the day after the delivery of the UK. With this service you can buy UK Sleeping Pills and deliver them to the door within 24 hours. The facility and speed of buying online sleeping pills in the UK can make a big difference for someone suffering from back-to-back sleepless nights. Getting rapid relief means avoiding long -term mental and physical consequences of ongoing shortage of sleep. Safety is needed when choosing to Buy Sleeping Pills UK. Always look for licensed UK-based online pharmacies registered with medicines and health product regulation agency (MHRA). These sites will usually need to fill out a medical questionnaire, which will be reviewed by a qualified health care provider. Avoid websites that provide sleeping pills without any kind of consultation or prescription. These sites can sell false or irregular medicines that may be dangerous to your health. When you use a valid supplier, your consultation, approval and distribution process is handled by professionals and safe. If you are looking for the best sleeping pills available in the UK, Zopiclone and Zolpidem are two of the most prescribed drugs for insomnia. Zopiclone is often available at 7.5 mg tablet and is known to help individuals quickly sleep and sleep at night. Zolpidem, a more widespread drug, has a similar effect and is often preferred for its little life, which reduces the possibility of growing the next day. In addition to these recipe options, natural sleep aids such as melatonin-based supplements, valerian root or antihistamine can also be purchased for Miller symptoms. The opportunity to buy online sleeping pills in the UK provides many benefits. First of all, you save time by avoiding commercial appointments and pharmacy visits. Second, online pharmacies often offer better prices and proper packaging. Third, the next day's delivery lets you address immediate sleep problems without delay. You can also review different product options, customers can read reviews and get medical guidance without leaving home. This availability has purchased the Go-to method for many people who relieve insomnia and other sleep problems in the UK. Click Here to Buy Sleeping Pills Online at UK Sleep Care. It is important to consider the cause of your sleeplessness before you start taking some sleeping pills the UK. Stress, diet, irregular sleep routine and mental health disorders can all play a role in troubled sleep. While the drug can provide immediate relief, long -term solutions often include lifestyle changes. It is recommended to use sleeping pills for short -term support while improving sleep hygiene. This includes maintaining a steady sleep, reducing screen time before bedtime, limiting caffeine intake in the evening and creating a cool sleep environment. Sleep pills can be very effective for those who need quick relief from sleep evenings. However, they are not for everyone. People with a history of drug addiction, breathing problems or some chronic conditions should consult a doctor before using them. Fortunately, when you buy the UK from a well-known online pharmacy, you will get the right medical guidance to ensure that the drug is right for you. If you have tried to change natural means and lifestyle without success, a small course of prescribed British sleep pills can help reset the sleep cycle and improve your overall health. Sleep is important for your physical and mental welfare. Lack of sleep can lead to chronic fatigue, weak immune function, irritability and even depression. This is why quick access to the best sleeping pills with the next day's delivery is more than a luxury – this is a requirement for many. Being able to buy online sleeping pills in the UK gives you control of your sleep health supported health. Whether you work with jet intervals, stress or ongoing insomnia, access to effective drug the next day means that you no longer need to suffer through endless sleep evenings. For people struggling with poor sleep, quick access is important for effective treatment. Thanks to the Internet, it is much easier to Buy Sleeping Pills UK, and has been distributed the following day. Whether you are looking for treatment or prescription solutions, reliable online pharmacies in the UK provide safe, practical and professional service. Sleep should not be a luxury. If you are ready to control your nights and restore your days, consider the facility to buy online sleeping pills in the UK with delivery in the UK the following day. TIME BUSINESS NEWS


Associated Press
3 hours ago
- Associated Press
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Company's Board of Directors (Board) effective June 4, 2025. 'We are delighted to welcome Maha as a new member of Candel's Board,' said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. 'Her extensive industry experience will be extremely valuable as Candel advances its late-stage oncology programs toward potential approval and commercial development, with the aim of providing benefit to patients with significant unmet need.' Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) submission for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026. 'I am honored to join the Board at this pivotal moment as Candel advances its innovative immunotherapy candidates across multiple cancer indications,' said Dr. Radhakrishnan. 'Candel's multimodal approach has the potential to address significant unmet needs in cancers that have historically been difficult to treat with conventional immunotherapies.' Dr. Radhakrishnan has over 20 years of experience advancing large strategic portfolios across various therapeutic areas through product development and commercialization within major biotechnology and pharmaceutical companies. Since August 2024, Dr. Radhakrishnan has served as an Executive Partner at Sofinnova Investments, a venture capital firm focused on life sciences, where she leads diligence across clinical-ready assets in multiple therapeutic areas and provides expertise to portfolio companies in product development and commercialization. Previously, Dr. Radhakrishnan served as Group Senior Vice President and Chief Medical Officer at Biogen Inc. Earlier in her career, she was Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi S.A. Dr. Radhakrishnan has also held leadership roles at Bioverativ, Inc., Bristol-Myers Squibb Company, UnitedHealth Group, Inc., and Cephalon, Inc. She received her M.D. with honors from the People's Friendship University in Moscow, Russia. 'Maha's expertise will be invaluable as we look forward to her contributions while we prepare to submit our Biologics License Application for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026,' said Paul B. Manning, Chairman of Candel's Board. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the submission of the Biologics License Application for CAN-2409 in intermediate-to-high-risk localized prostate cancer; and expectations regarding the therapeutic benefit of the Company's platforms. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. [email protected] Media Contact: Ben Shannon ICR Healthcare [email protected]